Heparin and low-molecular-weight heparin therapy for venous thromboembolism: Will unfractionated heparin survive?

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue SUPPL. 1, 2004, Pages 11-23

  Hull, Russell D ^a,b   Pineo, Graham F ^b  

^a FOOTHILLS HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Heparin; Low molecular weight heparin; Venous thromboembolism

Indexed keywords

ARGATROBAN; DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DEMINERALIZATION; DOSE CALCULATION; DRUG EFFECT; DRUG MONITORING; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; OSTEOPOROSIS; OUTCOMES RESEARCH; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

DRUG MONITORING; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 1842608583     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-822999     Document Type: Conference Paper

References (107)

1. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134-144
2. Wheeler HB, O'Donnell JA, Anderson FA Jr, et al. Occlusive impedance phlebography: a diagnostic procedure for venous thrombosis and pulmonary embolism. Prog Cardiovasc Dis 1974;17:199-205
3. Hull RD, Hirsh J, Sackett DL, et al. Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis: an alternative to venography. N Engl J Med 1977;296:1497-1500
4. Hull RD, Carter CJ, Jay RM, et al. The diagnosis of acute, recurrent, deep-vein thrombosis; a diagnostic challenge. Circulation 1983;67:901-906
5. Dalen JE, Brooks HL, Johnson LW, et al. Pulmonary angiography in acute pulmonary embolism: indications, techniques, and results in 367 patients. Am Heart J 1971;81:175-185
6. Brookstein JJ, Silver TM. The angiographic differential diagnosis of acute pulmonary embolism. Radiology 1974;110:25-33
7. Hull RD, Hirsh J, Carter C, et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest 1985;88:819-828
8. The PIOPED Investigators Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990;263:2753-2759
9. Salzman EW, Deykin D, Shapiro RM, et al. Management of heparin therapy: Controlled prospective trial. N Engl J Med 1975;292:1046-1050
10. Glazier RL, Crowell EB. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 1976;236:1365-1367
11. Mant MJ, O'Brien BD, Thong KL, et al. Haemorrhagic complications of heparin therapy. Lancet 1977;1:1133-1135
12. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-1114
13. Brandjes DP, Heijboer H, Büller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-1489
14. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a 'standard care' nomogram. Ann Intern Med 1993;119:874-881
15. Hull RD, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin treatment of venous thrombosis. N Engl J Med 1979;301:955-958
16. Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-327
17. Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985;39:631-636
18. Barzu T, Molho P, Tobelem G, et al. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv Rev Fr Haematol 1984;26:243-247
19. Bjornsson T, Wolfram BS, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982;31:104-113
20. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-145
21. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-1935
22. Hoppensteadt D, Walenga JM, Fasanella A, et al. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995;77:175-185
23. Levine M, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56
24. Fennerty A, Thomas P, Backhouse G, et al. Audit of control of heparin treatment. BMJ 1985;290:27-28
25. Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep-venous thrombosis. Arch Intern Med 1988;148:1321-1325
26. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-337
27. Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997;157:2562-2568
28. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-1595
29. Brill-Edwards P, Ginsberg J, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-109
30. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-1264
31. Campbell NR, Hull RD, Brant RF, et al. Aging & heparin related bleeding. Arch Intern Med 1996;156:857-859
32. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991;10:1-34
33. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-1292
34. Kelton JG, Sheridan D, Brain H, et al. Clinical usefulness of testing for a heparin-dependent platelet aggregation factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 1984;103:606-612
35. Greinacher A, Michels I, Krefel V, et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991;66:734-736
36. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69:344-350
37. 14C] serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995;104:648-654
38. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia: recommendations of the College of American Pathologists. Arch Pathol Lab Med 2002;126:1415-1423
39. Warkentin TE. Current agents for the treatment of patients with heparin-induced thrombocytopenia. Curr Opin Pulm Med 2002;8:405-112
40. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(suppl):64-94
41. Anand S, Ginsberg J, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996;156:1677-1681
42. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982
43. Sacks H, Berrier J, Reitman D, Ancora-Beck V, Chalmers T. Meta-analyses of randomized controlled trials. N Engl J Med 1987;316:450-455
44. Greenland S. A critical look at some popular meta-analytic methods. Am J Epidemiol 1994;140:290-296
45. Olkin I. A critical look at some popular meta-analytic methods. Am J Epidemiol 1994;140:297-299
46. Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. Arch Intern Med 1997;157:2317-2321
47. Topol EJ, Galliff RM, Welsman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-886
48. The GUSTO Angiographic Investigators The effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:71615-71622
49. Late Assessment of Thrombolytic Efficacy (LATE) Study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-766
50. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445
51. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-1546
52. Elliott CG, Hiltunen S, Suchyta M, et al. Physician-guided treatment compared with a heparin protocol for deep-vein thrombosis. Arch Intern Med 1994;154:999-1004
53. Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weight-based nomogram as a practice guideline. Arch Intern Med 1996;156:1645-1649
54. Levine M, Gent M, Hirsh J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681
55. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682-687
56. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17
57. Fareed J, Walenga JM, Hoppensteadt D, Huan S, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis 1988;18(suppl 3):3-15
58. Bara L, Samama MM. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1988;543(suppl):65-72
59. a effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989;61:348-353
60. Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Soderstrøm G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979;15:531-541
61. Fareed J, Walenga JM, Racanelli A, Hoppensteadt D, Huan X, Messmore HL. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Haemostasis 1988;3(suppl):33-47
62. Barrowcliffe TW, Curtis AD, Johnson EA, Thomas DP. An international standard for low molecular weight heparin. Thromb Haemost 1988;60:1-7
63. Holmer E, Soderberg K, Bergqvist D, Lindahl U. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis 1986;16(suppl 2):1-7
64. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982;59:1239-1245
65. Cade JF, Buchanan MR, Boneu B, et al. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984;35:613-625
66. Andriuoli G, Mastacchi R, Barbanti M, Sarret M. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis 1985;15:324-330
67. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular- weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-19
68. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-809
69. Dolovich LR, Ginsberg JS, Douketis DID, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188
70. van den Belt AG, Prins MH, Lensing AW, et al. Fixed dose subcutaneous low-molecular weight heparin versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2000;CD001100. Available at www.cochrane.org
71. Dalman TC, Lindvall N, Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post-partum. Br J Obstet Gynaecol 1990;97:221-228
72. Douketis DID, Ginsberg JS, Burrows RF, et al. The effects of long-term heparin therapy during pregnancy on bone density: a prospective matched cohort study. Thromb Haemost 1996;75:254-257
73. Monreal M, Vinas L, Monreal L, Lavin S, Lafoz E, Angles AM. Heparin-related osteoporosis in rats. A comparative study between unfractionated heparin and a low-molecular-weight heparin. Haemostasis 1990;20:204-207
74. Matzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost 1990;63:505-509
75. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995;86:1368-1373
76. Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. Thromboprophylaxis with low-molecular weight heparin (Dalteparin) in pregnancy. Thromb Res 1999;96:275-282
77. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002;87:180-181
78. Muir JM, Hirsh J, Weitz JL, et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997;89:3236-3242
79. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1374-1376
80. Lindhoff-Last E, Nakov R, Misselwitz F, et al. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol 2002;118:1137-1142
81. Wilson SJ, Wilbur K, Burton E, et al. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001;31:42-48
82. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavyweight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002;87:817-823
83. Harenbetg J. Fixed dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis. Curr Opin Pulm Med 2002;8:383-388
84. Forestier F, Daffos F, Capeila-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984;34:557-560
85. Andrew M, Cade J, Buchanan MR, et al. Low-molecular-weight heparin does not cross the placenta. Thromb Haemost 1983;50(suppl):225(abst)
86. Omri A, Delaloye FJ, Anderson H, Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989;61:55-56
87. Nelson-Piercy C, Letsky EA, deSwiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997;176:1062-1068
88. Wahlberg TB, Kher A. Low molecular weight heparin as thromboprophylaxis in pregnancy. A retrospective analysis from 14 European clinics. Haemostasis 1994;24:55-56
89. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119:122S-131S
90. Hyers TN, Agnelli G, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-193S
91. Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985;54:813-817
92. Holm HA, Ly B, Handeland GF, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16:30-37
93. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): results of a double-blind randomized study. Circulation 1989;80:935-940
94. Bratt G, Aberg W, Johansson M, Tomebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990;64:506-510
95. Harenberg J, Huck K, Bratsch H, et al. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis 1990;20(suppl 1):205-219
96. Siegbahan A, Y-Hassan S, Boberg J, et al. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo, Thromb Res 1989;55:767-778
97. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicentre trial. Thromb Haemost 1992;68:14-18
98. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-190
99. The Columbus Investigators Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662
100. Decousus H, Leizorovicz F, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409-415
101. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202
102. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin (letter). Lancet 1992;339:1476
103. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs. intravenous heparin. An economic perspective. Arch Intern Med 1997;157:289-294
104. van den Belt AGM, Bossuyt PMM, Prins MH, Gallus AS, Büller HR. for the TASMAN Group Replacing inpatient care by outpatient care in the treatment of deep vein thrombosis: an economic evaluation. Thromb Haemost 1998;79:259-263
105. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. N Engl J Med 1997;337:663-669
106. Hull RD, Raskob GE, Brant RF, et al. Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000;160:229-236
107. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000;83:209-211